Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 10.80
+0.05 (0.47%)
Jul 3, 2026, 5:23 PM CET
Xbrane Biopharma AB Market Cap
Xbrane Biopharma AB has a market cap or net worth of 222.54 million as of July 2, 2026. Its market cap has decreased by -39.98% in one year.
Market Cap
222.54M
Enterprise Value
212.67M
Revenue
76.45M
Ranking
n/a
PE Ratio
2.10
Stock Price
10.80
Market Cap Chart
Since February 3, 2016, Xbrane Biopharma AB's market cap has increased from 131.05M to 222.54M, an increase of 69.81%. That is a compound annual growth rate of 5.21%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 3, 2026 | 222.54M | 5.88% |
| Dec 30, 2025 | 210.17M | -14.54% |
| Dec 30, 2024 | 245.94M | -17.28% |
| Dec 29, 2023 | 297.31M | -86.83% |
| Dec 30, 2022 | 2.26B | -13.94% |
| Dec 30, 2021 | 2.62B | 58.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ascelia Pharma AB | 395.26M |
| Mendus AB | 355.21M |
| Isofol Medical AB | 235.88M |
| Initiator Pharma | 184.82M |
| Elicera Therapeutics AB | 178.19M |
| Xintela AB | 173.11M |
| Nanologica AB | 159.12M |
| Diamyd Medical AB | 158.08M |